← Leaderboards
Peter B Heifetz
Orpro Therapeutics, Inc.
$2,644,564
Attributed
$2,644,564
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,644,564 · 4
By mechanism
R44$1,724,117 · 1
R41$508,988 · 1
R43$411,459 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mucous Body Substance”
- Prescott G Woodruff · University Of California San Francisco$38,863,081
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$35,028,594
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Richard C Boucher · University Of North Carolina Chapel Hill$28,281,616
- John V Fahy · University Of California San Francisco$20,401,406
- Michael Jay Holtzman · Washington University$20,317,899
Research focus
Mucous Body SubstanceDisulfidesLung DiseasesActive SitesAffectProteinsEnzymesEscherichia ColiVariantPharmaceutical PreparationsMedicalLungMucinsInhalationChronicIn VitroDrug KineticsBaseEngineeringCystic FibrosisInfectionInflammationDoseIn Vivo
Grant awards (5)
Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury$508,988
R41 · FY2025 · HL · contact PI
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis$1,499,635
R44 · FY2018 · HL · contact PI
Mucoadhesive drug conjugates for controlled-release inhalation delivery$228,370
R43 · FY2018 · HL · contact PI
Development of modified human thioredoxin as an inhaled biologic therapeutic for cystic fibrosis$224,482
R44 · FY2018 · HL · contact PI
Development of human thioredoxin as a mucolytic therapy for Cystic Fibrosis$183,089
R43 · FY2012 · HL · contact PI